Proseek Bio develops high-accuracy blood tests for ovarian cancer utilizing a platform that detects multiple glycoform biomarkers simultaneously. This approach enhances diagnostic accuracy by analyzing protein sugars, which are often overlooked by traditional tumour markers. The validated diagnostic tests are designed for easy integration into existing clinical mass spectrometers without requiring new equipment.
Funding
Funding not disclosed
Founders
Product
Problem
Delayed diagnosis of ovarian cancer and other gynecological conditions leads to poorer patient outcomes and increased mortality rates. Current diagnostic methods often lack the necessary sensitivity and specificity for early detection, contributing to a significant diagnostic gap.
Solution
Proseek Bio develops advanced blood-based diagnostics designed for early detection of ovarian cancer and other gynecological conditions. The platform analyzes multiple glycoform biomarkers simultaneously, enhancing diagnostic accuracy and reducing the incidence of false positives. These validated and scalable diagnostics integrate seamlessly into existing laboratory workflows without requiring new equipment. By providing faster and more precise results, Proseek Bio aims to improve clinical decision-making and accelerate the time to diagnosis for women.
Target Audience
Primary customers include pathology laboratories seeking validated, scalable diagnostic solutions and general practitioners/specialists requiring faster, more accurate diagnostic information for their patients.
Features
- Multi-biomarker glycoform analysis for improved diagnostic sensitivity and specificity.
- Blood-based assay compatible with standard clinical mass spectrometers, ensuring broad laboratory adoption.
- No requirement for new reagents or specialized instrumentation.
- Validated biomarkers licensed from leading medical research institutes.
- Scalable platform designed for high-throughput clinical laboratory use.
- Development pipeline includes tests for differential diagnosis of pelvic masses, screening of high-risk populations, and initial diagnosis of autoimmune conditions.